Peptide therapy stories

Jul 24, 2026

FDA Advisory Panel Recommends Easing Restrictions on Unapproved Peptides Despite Agency Scientists' Concerns

Outside advisers to the U.S. Food and Drug Administration narrowly voted to recommend broader access to several unapproved peptides popular in wellness circles, backing a push by HHS Secretary Robert F. Kennedy Jr. despite objections from FDA career scientists about limited safety data and potential conflicts of interest among panelists.

Jul 24, 20268 sources

00

Jul 22, 2026

FDA panel votes to allow compounding of peptide BPC-157

FDA advisory panel voted to place peptide BPC-157 on a list allowing broader pharmacy compounding, the first of seven peptides under review. The decision supports HHS Secretary RFK Jr.'s push to expand access to these compounds.

Jul 22, 20266 sources

00

Supplement regulation

Public healthcare

US health policy & drug pricing

BPC-157

Related timelines

Peptide therapy stories

FDA Advisory Panel Recommends Easing Restrictions on Unapproved Peptides Despite Agency Scientists' Concerns

FDA panel votes to allow compounding of peptide BPC-157

Related timelines

Iran War

US Congress

Venture capital funding

Strait of Hormuz blockage

Trump administration